



2nd International Cancer Study & Therapy Conference

February 20-22, 2017 Baltimore, USA

Is molecular breast imaging an appropriate modality for breast cancer screening?

Tanya W. Moseley, Gaiane M. Rauch, Beatriz E. Adrada
The University of Texas MD Anderson Cancer Center, USA

Less than 20 years ago the only weapons in the arsenal of breast oncologists were chemotherapy and tamoxifen. Today there are many molecules that can potentially target the known oncogenes. The discovery of HER2 and the development of trastuzumab pioneered the field of targeted therapy in breast cancer. Breast imagers partner with their oncology colleagues to screen for breast cancer and to evaluate response to therapy. Although mammography, breast ultrasound, and breast MRI are excellent imaging tools, molecular breast imaging (MBI) has the potential to become a screening modality.

Biography:

Tanya W. Moseley, MD has distinguished herself as an outstanding breast radiologist, clinician, and educator. Dr. Moseley received her Doctorate of Medicine with Honors at the University of Iowa College of Medicine in Iowa City, Iowa. She entered a Clinical Residency in Diagnostic Radiology at the Mayo Clinic Graduate School of Medicine in Rochester, Minnesota, and continued on at the Mayo Clinic in a Clinical Fellowship in Mammography and Thoracic Imaging. After completing her fellowship, Dr. Moseley joined Mayo Clinic as a Senior Associate Consultant, and then joined the Division of Diagnostic Imaging at MD Anderson Cancer Center in 2001. She serves the institution as a Professor of Diagnostic Imaging.